Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Next Previous
X
Search
Trial Profile

Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim
  • Indications Adenocarcinoma; Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRESENT
  • Sponsors Galena Biopharma

    • Most Recent Events

    • 29 Apr 2019 Results of the interim analysis, published in the Clinical Cancer Research
    • 09 Nov 2016 According to a Galena Biopharma media release, management will present the top-line data from the trial and its assessment of the results in conference call.
    • 09 Aug 2016 Company has initiated an investigation into the causes of the the Independent Data Monitoring Committee (IDMC) recommendation to stop the trial, according to a Galena Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top